Check Claims Before You Publish

Author Review — I. Ishii (summary)

Available metadata indicate a low citation footprint (h-index = 1; total citations = 5; 4 papers listed), heterogeneous topical output, and limited visible academic affiliations — suggesting an early-career or ambiguous-author identity with modest scholarly impact so far. Key domain outputs connected to the string "Ishii" in the BGPT raw data include high-quality genome and systems-neuroscience resources but not necessarily authored by the same individual; this raises identity disambiguation concerns that materially limit any strong inference about a single author named "I. Ishii" T. chilonis genome (Scientific Data 2025) and an extensive whole-brain c-Fos dataset attributed to an author named Ishii in 2025 (neuroscience) Whole-brain c-Fos mapping (Ishii-Morphine 2025).

Author Review — "I. Ishii" (detailed)

Evidence visualizations (raw-data driven)

Critical synthesis (evidence + interpretation)

1. Identity ambiguity — central limitation: the author profile you provided (h-index 1, 5 citations, 4 papers) is not co-registered with several high-quality items in the BGPT corpus that also contain the token "Ishii" (e.g., a chromosome-level genome paper and a whole-brain c-Fos dataset). Without author disambiguation (ORCID, full name, affiliation), conflating these records is scientifically unsound and will produce misleading evaluations.
2. Bibliometrics indicate low measurable impact: the supplied h-index (1) and citation count (5) place the named author at an early-career or low-publication-impact status in standard bibliometric terms (low citation accumulation). The raw metrics should be interpreted cautiously because small name variants can split citation counts (name disambiguation bias).
3. Heterogeneous topical signals in BGPT raw data: BGPT raw entries show strong, domain-leading works that include 'Ishii' in diverse contexts — a high-quality genome assembly with full data deposition and a large neuroscience dataset with open code/data (both with strong methodological transparency), and several entomology/ecology lab studies with clear experimental designs. Each of those works scores high on quality metrics in the raw-data extract, but authorship likely maps to different individuals or taxonomic name origins (e.g., Trichogramma chilonis Ishii is a species name) T. chilonis genome (Scientific Data 2025).
4. Examples of strong individual papers in the corpus (but uncertain authorship mapping):
   • The Trichogramma chilonis chromosome-level assembly (Scientific Data, 2025) uses PacBio HiFi + Hi-C + Illumina and deposits raw reads/assembly — indicates strong technical standards and reproducibility practices (data available at NCBI and Figshare) T. chilonis genome (Scientific Data 2025).
   • A comprehensive whole-brain c-Fos mapping study with BRANCH hierarchical testing (2025) supplies code (GitHub/BRANCH), DANDI/Figshare datasets, multi-modal validation (TRAP, MERFISH), and robust sample sizes for voxel/region analyses (Nsubject ≈ 43), indicating high methodological sophistication and transparency in that specific dataset; again, authorship name overlap exists but should not be conflated without disambiguation Whole-brain c-Fos mapping (Ishii-Morphine 2025).
   • Several entomology papers (ENTOMON) on Trichogramma chilonis behaviour, enzyme profiles, and insecticide effects report reproducible lab protocols and clear sample-size statements — moderate-to-strong within their subfield, but they are domain-specific and not necessarily high-citation works Carbosulfan effects on T. chilonis (ENTOMON 2024).
5. Conflicts of interest and funding transparency: Individual extracted papers show reasonable funding disclosures (e.g., Taishan Scholars, National Key R&D for genome paper; FMC‑India declared in the Carbosulfan study). Where industry funding appears (Carbosulfan), interpret results with appropriate skepticism for sponsor bias; where open-data and code are provided (genome, whole-brain dataset), that strengthens credibility.
6. Reproducibility & openness: Several BGPT-listed items include explicit data deposition (NCBI, Figshare, GitHub, DANDI) and methodological detail (software/tools listed, sample sizes), which is strong evidence for reproducibility for those particular works. However, reproducibility of the author profile as a whole is limited by name disambiguation and uneven data-sharing across all 'Ishii'-tagged records.

Concrete recommendations (for you / for evaluating 'Ishii')

• Provide disambiguating metadata (full given name, ORCID, institutional affiliation, email) so BGPT and bibliometric systems can correctly merge citations and papers.
• Where possible, centralize data/code links (GitHub, Figshare, NCBI accession numbers) on an author page — this increases reproducibility and measurable impact.
• Declare funding & conflicts clearly on each paper; when industry funding exists, pre-register analysis plans or provide independent replication to reduce sponsorship-bias concerns.
• For early-career researchers: target a small number of high-transparency datasets/papers (with open data/code and explicit methodology) to accelerate citation accrual and reputational signal strength.

Selected primary-source citations used in this review

• T. chilonis genome (Scientific Data 2025)
• Ishii Morphine whole-brain dataset (2025)
• Carbosulfan effects (ENTOMON 2024)